Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance

Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.66 better than the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.

GUIDANCE:

Biogen sees FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61. Biogen sees FY2021 revenue of $10.8-10.9 billion, versus the consensus of $10.76 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
• Premarket movers: Quest, Labcorp hit by CMS cuts